12012 — MIMEDI (Q190706): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get invo...) |
(Removed claim: financed by (P890): European Union (Q1)) |
||
| Property / financed by | |||
| Property / financed by: European Union / rank | |||
Revision as of 06:32, 26 February 2020
Project in France financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 12012 — MIMEDI |
Project in France financed by DG Regio |
Statements
10,211,026.83 Euro
0 references
13,614,711.32 Euro
0 references
1 December 2017
0 references
30 November 2021
0 references
Université de Franche-Comté
0 references
47°14'23.03"N, 6°0'44.14"E
0 references
25030
0 references
Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
0 references
Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English)
0 references
Identifiers
10341
0 references